Regular aspirin use and nasopharyngeal cancer risk: A case-control study in Italy

Matteo Di Maso, Cristina Bosetti, Carlo La Vecchia, Werner Garavello, Maurizio Montella, Massimo Libra, Diego Serraino, Jerry Polesel

Research output: Contribution to journalArticlepeer-review


Regular aspirin use has been associated to decreased risk of several cancers, but evidence on nasopharyngeal carcinoma is scanty. We conducted a hospital-based case-control study in Italy, enrolling 198 Caucasian patients with nasopharyngeal carcinoma. Controls were 592 cancer-free Caucasian patients admitted to the same catchment areas as cases; controls were frequency matched according to sex, age, and area of residence. Regular aspirin use was defined as taking at least one aspirin a week for at least 6 months. Three cases (1.5%) and 27 controls (4.5%) reported regular aspirin use (odds ratio=0.24; 95% CI: 0.07-0.87). The median duration of consumption was 15 months among cases and 60 months among controls. Although study findings should be considered with caution due to limited sample size, they provide further evidence on the protective effect of aspirin use in head and neck cancers.

Original languageEnglish
Pages (from-to)545-547
Number of pages3
JournalCancer Epidemiology
Issue number4
Publication statusPublished - Aug 1 2015


  • Aspirin use
  • Case-control study
  • Head and neck cancer
  • Nasopharyngeal carcinoma
  • Risk factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology


Dive into the research topics of 'Regular aspirin use and nasopharyngeal cancer risk: A case-control study in Italy'. Together they form a unique fingerprint.

Cite this